Apimeds Pharmaceuticals US, Inc. (APUS) - Net Assets
Based on the latest financial reports, Apimeds Pharmaceuticals US, Inc. (APUS) has net assets worth $8.16 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.25 Million) and total liabilities ($1.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Apimeds Pharmaceuticals US, Inc. for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.16 Million |
| % of Total Assets | 88.22% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Apimeds Pharmaceuticals US, Inc. - Net Assets Trend (2021–2024)
This chart illustrates how Apimeds Pharmaceuticals US, Inc.'s net assets have evolved over time, based on quarterly financial data. Check APUS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Apimeds Pharmaceuticals US, Inc. (2021–2024)
The table below shows the annual net assets of Apimeds Pharmaceuticals US, Inc. from 2021 to 2024. For live valuation and market cap data, see APUS company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.36 Million | -4361.31% |
| 2023-12-31 | $31.87K | +104.47% |
| 2022-12-31 | $-713.61K | -199.23% |
| 2021-12-31 | $-238.48K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apimeds Pharmaceuticals US, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 283635000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $79.04K | % |
| Other Components | $2.95 Million | % |
| Total Equity | $-1.36 Million | 100.00% |
Apimeds Pharmaceuticals US, Inc. Competitors by Market Cap
The table below lists competitors of Apimeds Pharmaceuticals US, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gratifii Ltd
AU:GTI
|
$8.30 Million |
|
Snipp Interactive Inc
V:SPN
|
$8.31 Million |
|
T.Krungthai Industries Public Company Limited
BK:TKT
|
$8.31 Million |
|
Advanced Biomed Inc. Common Stock
NASDAQ:ADVB
|
$8.31 Million |
|
ATAM VALVES ORD (BSE)
NSE:ATAM
|
$8.30 Million |
|
Checkin.com Group AB
ST:CHECK
|
$8.30 Million |
|
XPS Pensions Group PLC
LSE:XPS
|
$8.30 Million |
|
Yelooo Integra Datanet Tbk PT
JK:YELO
|
$8.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apimeds Pharmaceuticals US, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,871 to -1,358,121, a change of -1,389,992 (-4361.3%).
- Net loss of 1,389,990 reduced equity.
- Other factors decreased equity by 2.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.39 Million | -102.35% |
| Other Changes | $-2.00 | -0.0% |
| Total Change | $- | -4361.31% |
Book Value vs Market Value Analysis
This analysis compares Apimeds Pharmaceuticals US, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.02 | $0.66 | x |
| 2022-12-31 | $-0.06 | $0.66 | x |
| 2023-12-31 | $0.00 | $0.66 | x |
| 2024-12-31 | $-0.11 | $0.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apimeds Pharmaceuticals US, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-610.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.00 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-597.31K |
| 2023 | -2440.13% | 0.00% | 0.00x | 13.24x | $-780.88K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.25 Million |
Industry Comparison
This section compares Apimeds Pharmaceuticals US, Inc.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $158,075,952
- Average return on equity (ROE) among peers: -190.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | $8.16 Million | 0.00% | 0.13x | $8.30 Million |
| Aurora Cannabis Inc (ACB) | $1.68 Million | -10.54% | 0.00x | $155.50 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $4.91 Million |
| Akebia Ther (AKBA) | $5.23 Million | -1801.64% | 67.08x | $340.21 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $7.49 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $1.64 Billion |
| Amphastar P (AMPH) | $448.72 Million | 0.31% | 0.41x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $5.21 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $17.98 Million | 4.60% | 0.22x | $196.52 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.92 Million | -75.48% | 0.12x | $1.78 Billion |
About Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.